CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing ...

Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $33.00. The company’s ...

Shares of Pfizer Inc. (PFE) slipped nearly 1.5% on Tuesday afternoon, even as the pharmaceutical giant posted a stronger-than ...

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street's revenue and profit estimates in its fourth-quarter results. Analyst firm Edward Jones expects Pfizer's future growth to ...

With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as ...

Pfizer Inc. (PFE) exceeded Wall Street expectations in its fourth-quarter and full-year 2024 earnings report, bolstered by ...

Palantir Technologies stock is trading at its highest level on record after the company posted a big beat with its fourth-quarter results. Earnings per share were up annually by 75% to 14 cents, ...

The company said Tuesday that Grimace will reunite with his Irish uncle, Uncle O'Grimacey, bringing the mascot out of ...

The company will present an open house on the project at 6 p.m. on Wednesday, Feb. 5 at the Livingston Township Hall.

The colon cancer BRAFF mutation study is one of the first to be initiated under the FDA’s Project FrontRunner.

The EC has authorised the use of ViiV Healthcare’s Vocabria plus Rekambys from J&J for treating adolescents with HIV-1.